Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Evans

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinics in Dermatology|October 12, 2000
Cutaneous viral infections in HIV-infected individualsA Yen-Moore, M Vander Straten, D Carrasco, et al.
Leukemia|July 28, 2007
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemiaJ F Dijoseph, M M Dougher, D C Armellino, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2010
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOPJohn F DiJoseph, Maureen M Dougher, Deborah Y Evans, et al.
Journal of the American Academy of Dermatology|May 13, 1999
Herpes gestationis in a mother and childS H Chen, K Chopra, T Y Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641R J Heaslip, L J Lombardo, J M Golankiewicz, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinics in Dermatology|October 12, 2000
Cutaneous viral infections in HIV-infected individualsA Yen-Moore, M Vander Straten, D Carrasco, et al.
Leukemia|July 28, 2007
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemiaJ F Dijoseph, M M Dougher, D C Armellino, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2010
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOPJohn F DiJoseph, Maureen M Dougher, Deborah Y Evans, et al.
Journal of the American Academy of Dermatology|May 13, 1999
Herpes gestationis in a mother and childS H Chen, K Chopra, T Y Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641R J Heaslip, L J Lombardo, J M Golankiewicz, et al.
Pageof 4